-
June 17: The Week in Cancer News
Clinical trials rebound after COVID-19 setbacks, and early treatment leads to significant reduction in anal cancer risk among people with HIV.
by Thomas Celona
-
A Look at Disparities Across Cancer Care
A new AACR report tracks progress in addressing cancer health disparities and identifies work that still needs to be done.
by Eric Fitzsimmons
-
Credit Agencies to Remove Some Medical Debt From Reports
Changes to what medical debt is included in credit reports could give patients more time to resolve outstanding bills.
by Karon Warren
-
June 10: The Week in Cancer News
Patients who lose weight through bariatric surgery have a lower cancer risk, and a HER2-targeted therapy gets striking results in HER2-low breast cancer patients.
by Kevin McLaughlin
-
June 3: The Week in Cancer News
Contrast dye shortage delays scans for cancer, and more public assistance linked to higher survival rates for Black cancer patients.
by Eric Fitzsimmons
-
May 27: The Week in Cancer News
A blood test could help determine who benefits from checkpoint inhibitors in lung cancer, and the FDA approves a drug combination for certain patients with acute myeloid leukemia.
by Marci A. Landsmann
-
May 20: The Week in Cancer News
Esophageal cancer increases in the middle-aged, and adolescent and young adult leukemia survivors face continued mortality risk after treatment ends.
by Eric Fitzsimmons
-
The Mental Toll of a Cancer Diagnosis
New studies shine a light on the effects of a cancer diagnosis on mental health and suicide risk.
by Pamela Rafalow Grossman
-
May 13: The Week in Cancer News
First child to receive CAR T-cell therapy celebrates 10 years cancer-free, and authorization denials delay treatment for patients with Medicare Advantage.
by Marci A. Landsmann
-
May 6: The Week in Cancer News
Adolescents and young adult cancer survivors at higher risk for dying from a new cancer diagnosis, and FDA grants full approval to Enhertu for metastatic HER2-postive breast cancer.
by Eric Fitzsimmons
Cancer Talk
Treating HER2-ultralow Breast Cancer
FDA approval expands treatment options for people with metastatic breast cancer that expresses minimal levels of HER2.
by Sandra Gordon
Lessons Learned as a Caregiver and PatientAfter caring for her husband during his cancer treatment, Miriam Díaz-Gilbert was prepared to face her DCIS diagnosis.
by Miriam Díaz-Gilbert
Screening Options for People With Dense BreastsReports on breast density inform women of their status but raise questions about what to do next.
by Robin Roenker
Injection Immunotherapies Get FDA ApprovalGiving immunotherapy drugs as injections, rather than intravenously, means patients can spend less time in the hospital or treatment center.
by Laura Gesualdi-Gilmore